Howard Hughes Medical Institute / University of Geneva / University of California San Francisco / Salk Institute / Rockefeller University / /
IndustryTerm
active site / pharmacological tool / cancer therapies / treatment of cancer / pharmacological tools / internal ribosome entry site / viral internal ribosome entry site / important site / /
MedicalCondition
cancers / cancer / serum starvation / human disease / dissociation / /
MedicalTreatment
immunosuppression / cancer therapies / /
Organization
National Institute of Health / University of California San Francisco / San Francisco / Rockefeller University / New York / School of Medicine / Salk Institute for Biological Studies / Department of Molecular Biology / University of Geneva / Helen Diller Family Comprehensive Cancer Center / Department of Cellular and Molecular Pharmacology / Howard Hughes Medical Institute / Department of Urology / /
Person
Tony Hunter / /
Position
Author / original author / well-established bicistronic reporter / Major / representative / reporter / www.plosbiology.org Academic Editor / /
PLoS BIOLOGY Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 Morris E. Feldman1, Beth Apsel1, Aino Uotila2, Robbie Loewith2, Zachary A. Knight1¤, Davide Ruggero3,